Oxford BioMedica (LSE:OXB) has appointed Dr Joachim Kreuzburg, former chief executive of Sartorius, as an independent non-executive director, effective 23 November 2026.
The FTSE 250-listed cell and gene therapy contract development and manufacturing organisation (CDMO) said the appointment will add experience in life sciences technologies, international operations and mergers and acquisitions to its board.
Kreuzburg previously led Sartorius, a supplier of equipment and technologies to the biopharmaceutical industry, and brings experience in managing businesses operating within the life sciences sector.
The appointment comes as Oxford BioMedica continues developing its international manufacturing network and providing viral vector development and production services to pharmaceutical and biotechnology customers.
Board Appointment Adds Life Sciences and M&A Experience
Oxford BioMedica said Kreuzburg’s background includes executive leadership in life sciences technologies and experience in corporate acquisitions and business development.
His appointment as an independent non-executive director will take effect on 23 November 2026.
The company’s chair identified Kreuzburg’s industry experience as relevant to Oxford BioMedica’s plans for developing its international CDMO operations.
Kreuzburg also commented on opportunities within the cell and gene therapy sector and indicated that he intends to contribute to the company’s plans for expanding its manufacturing and development activities.
The appointment adds a director with experience in the broader biopharmaceutical technology and manufacturing industry as Oxford BioMedica continues operating across multiple international markets.
Oxford BioMedica Operates Manufacturing Facilities Across Three Countries
Oxford BioMedica provides contract development and manufacturing services for companies developing cell and gene therapies.
The Oxford-headquartered group operates facilities in the United Kingdom, France and the United States, supporting customers at different stages of therapy development and manufacturing.
Its services cover activities ranging from early-stage development to manufacturing associated with commercialisation.
The company’s international operations provide access to manufacturing infrastructure and technical capabilities for pharmaceutical and biotechnology businesses requiring viral vectors for advanced therapies.
Oxford BioMedica has developed its manufacturing network to support multiple viral vector technologies, including lentiviral, adeno-associated viral (AAV) and adenoviral systems.
Viral Vector Technologies Support CDMO Services
Oxford BioMedica has more than three decades of experience in viral vector development and manufacturing.
Its technology portfolio includes the fourth-generation TetraVecta lentiviral system and AAV production technologies used in the development and manufacture of cell and gene therapies.
The company works with pharmaceutical and biotechnology customers requiring specialist manufacturing processes, analytical services and regulatory support.
These capabilities are used across different stages of product development, from initial research and process development through to manufacturing for clinical and commercial applications.
Oxford BioMedica’s activities also include quality control and analytical processes associated with the production of viral vectors.
The group continues to develop its manufacturing platforms and international operations as part of its strategy to provide CDMO services across different viral vector technologies.
Appointment Supports International Business Development Plans
The addition of Kreuzburg to the board comes as Oxford BioMedica maintains operations across Europe and North America.
Management has identified international business development and the expansion of its CDMO activities as areas of focus.
Kreuzburg’s experience in life sciences equipment, technologies and acquisitions is expected to contribute to board discussions covering the company’s operational development and corporate strategy.
Oxford BioMedica continues to work with biopharmaceutical customers developing viral vector-based treatments, with its manufacturing and technology platforms forming the basis of its service offering.
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a FTSE 250-listed contract development and manufacturing organisation headquartered in Oxford, United Kingdom.
The company specialises in viral vector development and manufacturing for cell and gene therapies, providing services to pharmaceutical and biotechnology customers.
Its operations span the United Kingdom, France and the United States, with manufacturing capabilities covering lentiviral, AAV, adenoviral and other viral vector technologies.
Oxford BioMedica’s services include process development, analytical testing, quality management and manufacturing support for therapies progressing through clinical development and commercialisation.
Leave a Reply